OR WAIT null SECS
WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.
On June 1, 2023, contract research, development, and manufacturing organization WuXi Biologics (WuXi Bio) announced that it will increase its manufacturing capacity at two of its sites in Germany. The expansion will include drug substance and drug product manufacturing capacity.
At Chempark Leverkusen, Germany, the company’s sterile filling and freeze-drying plant for drug products, WuXi Bio will add a second variable filling line. The Leverkusen site currently has an annual capacity of approximately 10 million doses. At Wuppertal, Germany, the company’s drug substance facility, WuXi Bio intends to double total capacity from 12,000 L to 24,000 L on 30,000 m2.
The two site expansions will enhance WuXi Bio’s clinical and commercial manufacturing capacities in Europe and will strengthen its global dual-sourcing network strategy. Doing so will ensure that materials can be sourced and products manufactured at multiple sites within the company’s network, according to a company press release.
"The investment in our facilities in Germany will add new capacity and enhance our existing manufacturing services, which will strengthen our team’s ability to deliver timely support to our global clients to advance their biologics towards commercialization," said Chris Chen, CEO of WuXi Biologics, in the press release.
"WuXi Biologics’ increased capacity in Germany is intended to meet the growing needs of our global customers, especially those in Europe, thereby aligning us with the company's global strategy to work in close proximity to our clients. Germany is a leading biotech and pharma hub. The expansion of the two facilities is a clear commitment to Germany and Europe as high-tech locations and WuXi Biologics’ long-term growth strategy," said Benjamin Minow, managing director of WuXi Biologics Germany, in the release.
Source: WuXi Biologics